Introduction: Currently, there is no approved therapeutic entity for coronavirus disease 2019
(COVID-19) and clinicians are primarily relying on drug repurposing. However, findings …

Introduction: The coronavirus disease 2019 (COVID-19) caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It …

Coronavirus disease-2019 (COVID-19) is a respiratory tract infection accompanied by
severe or fatal pneumonia-like symptoms and sometimes death. It has posed to be an …

Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …

Objectives This study was designed to compare the efficacy and safety of
methylprednisolone and tocilizumab in the treatment of patients with severe COVID-19 …

Purpose A recent survey has shown that the COVID-19 pandemic has culminated in
dramatical and critical treatment particularly in acute infected patients. In fact, this systematic …

Background: Coronavirus disease (COVID-19) caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an …

Identifying effective and safe therapies for the management of patients with coronavirus
disease 2019 (COVID-19) is crucial in the control of the pandemic. The critical role of …

Purpose Tocilizumab has shown equivocal outcomes in reducing mortality in COVID-19.
The corticosteroids appear to be an affordable alternative to tocilizumab. This study aims to …

Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …